Navigation Links
Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
Date:8/6/2014

esearch with Biogen Idec; Regulus to Receive $2M Upfront Payment.  Regulus entered into a new collaboration agreement with Biogen Idec to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis ("MS") under its Regulus microMarkers™ division.  The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures.  Regulus will receive $2.0 million upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.  Regulus and Biogen Idec began their collaboration in August 2012 to identify potential microRNA biomarkers in MS.  The results of this previous work helped define the scope of the research under the new collaboration agreement, which resulted in a termination of the August 2012 agreement.
  • Orphan Designation Granted to RG-012 from the U.S. Food and Drug Administration. Recently, the U.S. Food & Drug Administration granted orphan drug designation to RG-012, an anti-miR targeting microRNA-21 ("miR-21"), as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.  In the near term, Regulus expects to initiate a natural history of disease study to gather greater information about the progression of Alport syndrome and to inform future clinical development plans of RG-012.
    Under the 'Clinical Map Initiative', Regulus expects to initiate a Phase I clinical study of RG-012 in the first half of 2015.
  • Second Quarter 2014 Highlights

  • Phase I Clinical Study of RG-101 for the Treatment of HCV Ongoing. Regulus is evaluating RG-101, a GalNAc-conjugated anti-miR that targets microRNA-122 ("miR-122"), in a Phase I clinical study for the treatment of chronic hepatitis C virus infection ("HCV").  Th
    '/>"/>

  • SOURCE Regulus Therapeutics Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
    2. Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
    3. Regulus Announces Addition to NASDAQ Biotechnology Index
    4. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
    5. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
    6. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
    7. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
    8. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    9. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
    10. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
    11. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/1/2015)... 2015  Genoa has acquired West Bend Assisted Living ... pharmacy location with a proven track record for excellent ... settings, and those involved in their care. Both companies ... delivering true value to their customers. ... of pharmacy services dedicated to the behavioral health community ...
    (Date:7/1/2015)... July 1, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... Radie , president and chief executive officer, is ... He will provide an update on Egalet,s marketed ... Nasal Spray, approved product OXAYDO ™ (oxycodone ...
    (Date:7/1/2015)... FRANCISCO , July 1, 2015 ... market) is expected to reach USD 49,119.2 million by ... Research, Inc. Monitoring services is expected to remain the ... of USD 1,227.5 million in 2012, and an estimated ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse ...
    Breaking Medicine Technology:Genoa, a QoL Healthcare Company Acquires West Bend Assisted Living Pharmacy 2Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
    ... announced today that it has licensed technology from Yale University ... in the January issue of the journal Cell Cycle ... associated with breast cancer risk, such mutations in BRCA1 ... The research identified microRNA disrupting variants in and around ...
    ... N.J., Feb. 24, 2011 University Radiology Group, ... teleradiology services, is working with MedInformatix Inc. to ... to achieve Stage 1 meaningful use ... Reinvestment Act (ARRA) for Health Information Technology. ...
    Cached Medicine Technology:Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2University Radiology Group Works With MedInformatix to Meet Stage 1 Meaningful Use Qualifications 2University Radiology Group Works With MedInformatix to Meet Stage 1 Meaningful Use Qualifications 3
    (Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show hosted by ... 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event will ... zoo, an Elvis impersonator, a silent auction and concessions. , Horses and riders from ...
    (Date:7/1/2015)... ... ... Convoy of Hope will partner with local businesses, churches, government ... 1, at Spring Lake Park High School. , During the celebration, Convoy of Hope ... goods and services including free food, health services, family portraits, job services, a carnival ...
    (Date:7/1/2015)... KY (PRWEB) , ... July 01, 2015 , ... ... Care Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying the ... paper was published July 1st and is available at: http://www.hcttf.org/resouces-tools . , ...
    (Date:7/1/2015)... ... July 01, 2015 , ... Franklin University, one of the leading educators ... has been named Dean of the College of Health & Public Administration ... and support the vision and mission of Franklin University via curriculum planning, course scheduling, ...
    (Date:7/1/2015)... ... July 01, 2015 , ... ... summer sale. Customers purchasing two or more Bunion Booties directly from their ... , Bunion Bootie temporarily corrects misaligned toes and its ultra thin properties allow ...
    Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2
    ... Gerontological Society of America (GSA) the nation,s ... has chosen Alan Jette, PhD, of Boston University ... of Aging Persons Award. This distinguished honor is ... of rehabilitation. The awardee,s work may be in any ...
    ... be used to determine whether a lung cancer patient ... published in the August issue of the Journal ... the International Association for the Study of Lung Cancer ... been found to respond well to crizotinib, an ALK ...
    ... aero-digestive tract cancers (UADT), especially those of the oral cavity, ... as it has been shown repeatedly that heavy drinkers, in ... alcohol use and cigarette smoking is the key factor in ... distinguished group of scientists from the International Agency for Research ...
    ... sulfide is a foul-smelling gas with an odor resembling that ... is generally associated with decaying vegetation, sewers and noxious industrial ... it also plays a critical role in protecting blood vessels ... from the University of Texas Medical Branch at Galveston. ...
    ... (HealthDay News) -- Heart attack survivors who live in ... neighborhoods, a new study finds. Regular exercise after ... of survival, the Israeli researchers noted. In the ... more than 10 years to assess their levels of ...
    ... over 75 are likely to have at least one abnormal liver ... likely to die from cancer and 17 times more likely to ... of Alimentary Pharmacology and Therapeutics . UK researchers studied ... to an in-depth health assessment. Patients were drawn at random from ...
    Cached Medicine News:Health News:Jette to receive GSA's 2011 Excellence in Rehabilitation of Aging Persons Award 2Health News:The effects of smoking and alcohol use on risk of upper aero-digestive cancers 2Health News:Scientists show 'swamp gas' protects blood vessels from complications of diabetes 2Health News:Abnormal liver tests associated with increased death rates in people over 75 2Health News:Abnormal liver tests associated with increased death rates in people over 75 3
    Porous foundation 440 series....
    Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
    The Biopro optima stem is manufactured from cobalt chrome and is available in a Non-Porous coat option....
    The cemented hip joint prosthesis system....
    Medicine Products: